Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Glandokort iconGlandokortSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Glandokort

Beginner tier: 10 mg, daily · 4w on / 12w off · community consensus

MetabolicResearch
~1-4 hours half-life (estimated)·Oral

Also known as: A-17, Peptide Complex A-17, Glandocort

Thirty-six patients with chronic adrenal insufficiency took 10 mg twice daily for 30 days. That is the entire clinical evidence base for Glandokort, a Khavinson-class peptide bioregulator extracted from bovine adrenal cortex tissue. The study reported improved stress tolerance, normalized aldosterone, and better sleep. It was never published in an indexed journal, never replicated, and never blinded. Glandokort contains peptide complex A-17, short-chain peptides under 5,000 Da that supposedly bind adrenal gene promoter regions to upregulate steroidogenesis. Biohackers in the longevity community stack it with Epithalon and Pinealon for HPA axis support. Cost runs $4 to $5 per day for a standard 30-day course.

What Is Glandokort?

Glandokort (peptide complex A-17, no CAS number assigned) is an oral bioregulator containing short-chain peptides extracted from the adrenal cortex of young cattle or pigs. One clinical study exists: 36 patients, no placebo arm. That is the full evidence base. Each capsule holds roughly 10 mg of active peptides with molecular weights below 5,000 Da. The product comes from the Khavinson Institute of Bioregulation and Gerontology in St. Petersburg, the same group behind Epithalon, Pinealon, and the broader bioregulator research program spanning 40+ years.

The sole clinical study enrolled patients ages 37 to 62 with chronic adrenal cortex insufficiency (St. Petersburg Institute, April to November 2011). They took 1 capsule twice daily for 30 days alongside standard adaptogen therapy. Researchers tracked aldosterone, 17-ketosteroids, physical performance, and mood. All showed improvement compared to controls. The reticular adrenal zone showed restored metabolic activity, and hormonal markers returned to normal-range values.

That study was never published in a PubMed-indexed journal. No independent group has tried to replicate it in 15 years. No randomized, double-blind, placebo-controlled trial exists.

Community experience is limited too; fewer than 10 Reddit threads discuss Glandokort specifically. The users who do try it typically follow the original study protocol exactly: 10 mg twice daily for 30 days, repeated every 3 to 6 months. Most stack it with other Khavinson bioregulators rather than running it solo, which makes isolating its effects difficult. Anecdotal reports mention improved stress tolerance and better sleep, but placebo effects in burnout contexts are well-documented.

How Glandokort Works

Glandokort follows the same theoretical framework as all Khavinson bioregulators. Short-chain peptides (2 to 4 amino acid residues) from the A-17 complex are proposed to cross cell membranes and enter the nucleus of adrenal cortex cells. Once there, they bind specific DNA sequences on promoter segments of genes involved in adrenal steroidogenesis.

The proposed downstream effect is upregulation of enzymes in the cortisol, aldosterone, and androgen biosynthetic pathways. The clinical study's observation of increased aldosterone and 17-ketosteroid production points toward effects on CYP11B2 (aldosterone synthase) and DHEA-related pathways. That connection hasn't been confirmed at the molecular level.

Glandokort is also reported to reduce lipid peroxidation in adrenal tissue, suggesting antioxidant properties. Whether this is a direct peptide effect or a secondary consequence of improved cellular function remains unclear.

The broader Khavinson model has some published support. A 2021 systematic review [1] confirmed that short peptides can regulate gene expression. A study [2] showed short peptides interacting with DNA promoter regions in vitro. But these findings apply to the bioregulator class generally, not Glandokort specifically. No study has mapped which adrenal genes Glandokort's A-17 complex actually binds, at what affinity, or through what signaling cascade.

The mechanism is plausible within the Khavinson framework. It just hasn't been validated for this specific product.

Glandokort Benefits

  • Glandokort benefits center on adrenal cortex support and HPA axis function during chronic stress.
  • Aldosterone and 17-ketosteroid levels normalized in the sole clinical study (n=36, 10 mg twice daily for 30 days), suggesting direct effects on adrenal steroidogenesis.
  • Physical and mental performance scores improved compared to controls in patients with diagnosed adrenal cortex insufficiency (St. Petersburg Institute, 2011).
  • Sleep quality and mood stability improved by the end of the 30-day course, a finding that tracks with community reports of reduced burnout sensation.
  • No serious adverse events were reported during the clinical study or in available community reports, making it one of the better-tolerated Khavinson bioregulators.
  • Oral capsule format avoids injection, reconstitution, and bacteriostatic water entirely, which removes the barrier that stops many people from trying peptides in the first place.

Glandokort: Science vs Community Consensus

Aligned
Scientific Evidence
Weak
Based on 5 key studies·Research only

Single unindexed clinical study (n=36, 2011) from developer-affiliated institution showed improved physical/mental performance, mood, sleep, and normalization of aldosterone and 17-ketosteroids at 10 mg 2x daily for 30 days.

Dosing studied: 10–20 mg/day (1–2 capsules, 1–2x daily)
Read the evidence (key study, limitations)

No independent replications, no RCT, no placebo control.

Key Study

St. Petersburg Institute of Bioregulation and Gerontology clinical study (Apr–Nov 2011), n=36, ages 37–62, chronic adrenal cortex insufficiency, 10 mg 2x daily for 30 days with standard adaptogen therapy

Limitations

Unindexed (not in PubMed-indexed journal); no placebo arm; no blinding; single-institution, developer-affiliated; n=36 only; no independent replication in 15 years; no Glandokort-specific mechanistic confirmation at molecular level

Community Experience
Weak
3.0/5
Based on < 10 Reddit threads estimated

Very limited community discussion; niche use within Khavinson bioregulator adopters.

Community dosing: 10 mg 2x daily (most common; mirrors clinical study)
Read the reports (what users report 4, common issues 5)

Anecdotal reports of improved burnout recovery, stress tolerance, and sleep quality. No Reddit-specific protocol threads identified.

What users report (4)
  • Improved stress tolerance and reduced "fried nerves" / burnout sensation
  • Better sleep-wake cycle regulation
  • Improved energy and mood during chronic fatigue states
  • Felt as a subtle background stabilizer of HPA axis function
Common issues (5)
  • Very difficult to assess efficacy in isolation: almost always stacked with other bioregulators
  • Expensive relative to evidence base (~$4–$10/day depending on format)
  • No independent testing of active peptide content in third-party retail versions
  • Placebo effects in burnout/adrenal fatigue context are known to be significant
  • No community consensus separate from manufacturer-derived protocols
Science & Community Aligned

Community protocols mirror the sole clinical study protocol almost exactly (10 mg 2x daily, 30 days, repeated quarterly). Alignment is superficial: community is largely following manufacturer/Khavinson Institute guidance derived from the same study, not independent real-world convergence.

Glandokort Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner10 mgDaily
Moderate10 mg2x Daily
Aggressive20 mg2x Daily
Note:

Glandokort is an oral capsule. No reconstitution, no bacteriostatic water, no insulin syringes. You swallow it with food and water.

Standard protocol: 1 capsule (10 mg) twice daily with meals. Morning plus early afternoon. Skip the evening dose; adrenal stimulation before bed is a bad idea.

Run the course for 30 days. The manufacturer says 10 to 30 days, but the only clinical study used 30. Don't shortchange it.

After your course, take 3 to 6 months off before repeating. Most Khavinson bioregulator users run 2 to 3 courses per year.

One thing most beginners miss: you can't tell if Glandokort is working when you stack it with Epithalon, Pinealon, and three other bioregulators at once. Run a solo course first to establish your baseline response. Then stack on subsequent rounds.

Source quality matters here. The original Firma Vita product from Russia is the validated reference. US-market repackaged versions don't have independent peptide content verification. Pay attention to where your capsules actually come from.

Cycling Protocol

On Period
4 weeks
Off Period
12 weeks

Standard Russian protocol: 1-2 capsules twice daily with meals for 10-30 days, repeated 2-3 times per year.

Calculate your Glandokort dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Glandokort Protocols by Goal

beginnerClinical Trial30 days
Standard Course
Wk 4
10 mg · Twice daily · Oral (capsule)

Expected: Gradual improvement in stress tolerance, mood stability, sleep quality, and energy levels by weeks 3–4. Hormonal markers (aldosterone, 17-ketosteroids) showed normalization in the clinical study.

Monitor: No mandatory lab monitoring for oral bioregulators at standard doses. Optional: baseline and post-course AM cortisol and DHEA-S if tracking adrenal response quantitatively.

How to Inject Glandokort

  1. 1
    Take 1 capsule (10 mg) with your morning meal

    Swallow whole with a full glass of water. Don't open or chew the capsule.

  2. 2
    Step 2

    Take a second capsule (10 mg) with an early afternoon meal, ideally before 2 PM. This keeps dosing aligned with your natural cortisol rhythm. Total daily dose at the standard level: 20 mg.

  3. 3
    Step 3

    If using the intensive protocol (community-derived, not clinically studied): take 2 capsules (20 mg) with your morning meal and 2 capsules (20 mg) in the early afternoon. That's 40 mg per day and the upper bound of manufacturer labeling. No published evidence supports a dose-response advantage over 20 mg per day.

  4. 4
    Continue for 30 days

    Mark your start and end dates.

  5. 5
    Step 5

    After completing the course, wait 3 to 6 months before repeating. Most users settle on a quarterly schedule.

  6. 6
    Step 6

    Store capsules at room temperature (15 to 25 degrees Celsius / 59 to 77 degrees Fahrenheit). Keep them in original packaging, away from moisture and direct light.

  7. 7
    Step 7

    Optional lab monitoring: draw AM cortisol and DHEA-S at baseline (before the course) and again at days 35 to 40 (after the course) if you want to track your adrenal response quantitatively.

Glandokort Stacking Protocols

Works With

Avoid

Pharmaceutical corticosteroids (prednisone, hydrocortisone, dexamethasone)

Additive adrenal hormone effects are theoretically possible. Combined adrenal stimulation could disrupt HPA axis feedback. Use only under medical supervision if combination unavoidable.

Do not combine
Mineralocorticoid receptor antagonists (spironolactone, eplerenone)

Glandokort promotes aldosterone normalization; MR antagonists block aldosterone activity. Opposing mechanisms may reduce efficacy of both agents.

Estimated Cost

Brand Price
Firma Vita Glandokort® (original): ~$85–$100/20 caps (10-day supply at 2 caps/day); ~$135/60 caps (30-day supply at 2 caps/day)
Generic / Research
US retail repackaged (various): 60 caps $129–$135 (~$4.33–$4.50/day at standard 2 caps/day dose)

Pricing updated 2026-04-09

Glandokort Side Effects

The honest answer: nobody really knows the full side effect profile of Glandokort. The total published safety data comes from 36 people over 30 days in one unblinded study. That study reported zero adverse events. Zero. For a compound derived from animal adrenal tissue, that should be taken with appropriate skepticism rather than comfort.

No formal pharmacovigilance system monitors Glandokort. No post-marketing surveillance exists. The FDA has never reviewed it.

The theoretical risks start with the obvious. Glandokort contains bovine or porcine adrenal cortex peptide extract. Anyone with a known hypersensitivity to animal-derived proteins should avoid it. Allergic reactions to the Khavinson bioregulator class are documented rarely, but "rarely" in a population of a few hundred total users worldwide is a weak denominator.

Gastrointestinal discomfort is the most commonly mentioned issue in community reports. Oral peptide capsules can cause mild nausea or stomach upset, particularly when taken without food. This is consistent with other oral peptide products and typically resolves within the first few days of a course.

A more subtle concern involves HPA axis disruption. Glandokort is designed to stimulate adrenal cortex gene expression. In someone with already-normal adrenal function (as opposed to the diagnosed insufficiency in the clinical study), the effect of additional adrenal stimulation is unknown. The Khavinson model assumes bioregulators "normalize" function, implying they don't push healthy systems past baseline. That assumption has never been tested in a controlled setting for this product.

Evening dosing may interfere with sleep. Adrenal peptide activity could blunt the natural cortisol decline that triggers sleep onset. Community users have learned to dose in the morning and early afternoon only.

Combining Glandokort with pharmaceutical corticosteroids (prednisone, hydrocortisone, dexamethasone) creates a theoretical risk of additive adrenal stimulation and HPA axis disruption. Similarly, mineralocorticoid receptor antagonists like spironolactone or eplerenone work against aldosterone activity, which directly opposes what Glandokort is trying to do.

When to stop and consult a doctor: any signs of allergic reaction (rash, swelling, difficulty breathing), unusual agitation, persistent insomnia that started with the course, or symptoms suggesting cortisol excess (unexplained weight gain, facial puffiness, easy bruising). Pregnancy and breastfeeding are absolute contraindications; no safety data exists. Children under 18 should not use it.

The bottom line is that Glandokort's safety profile looks clean in a very small dataset. Absence of reported harm in 36 people is not the same as evidence of safety.

Common Issues & Solutions

No effects by day 10: Expected: mechanism is epigenetic gene expression modulation, not direct hormone stimulation. Effects build over the full 30-day course. Do not increase dose prematurely.

Evening use disrupting sleep: Shift all doses to morning and early afternoon only. Adrenal peptide activity may blunt the natural evening cortisol decline, interfering with sleep onset.

Cannot assess efficacy due to stacking: Run a solo Glandokort course (no other bioregulators) before stacking to establish your individual baseline response.

Course length confusion (10 vs 30 days): The manufacturer states 10–30 days; the only clinical study used 30 days. Use the full 30-day course for evidence-aligned results; 10-day protocols are not clinically supported.

Animal protein concern: Glandokort contains bovine or porcine adrenal cortex peptide extract. Not suitable for those with hypersensitivity to animal-derived proteins, vegans, or individuals with religious dietary restrictions.

Ask AI about this page

Ask AI for a second opinion on Glandokort dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (no safety data available)
  • Known hypersensitivity to animal-derived peptide preparations
  • Active adrenal tumors or Cushing's syndrome
  • Children under 18 (insufficient safety data)

Drug Interactions

  • Use caution with corticosteroid medications — additive effects on adrenal hormone levels are theoretically possible
  • May interact with mineralocorticoid receptor antagonists (spironolactone, eplerenone)
  • No formal drug interaction studies have been conducted
  • Additive adrenal hormone effects are theoretically possible. Combined adrenal stimulation could disrupt HPA axis feedback. Use only under medical supervision if combination unavoidable.

Product Quality

Recommended Monitoring

TestWhenTarget
AM cortisol (serum)Optional: baseline (pre-course) and post-course (days 35–40)AM cortisol: 6–23 mcg/dL (lab-dependent)
DHEA-SOptional: baseline and post-courseAge- and sex-adjusted normal ranges (wide variability)
Aldosterone (serum)Optional: if monitoring mineralocorticoid axis specificallyNormal (sitting): 4–31 ng/dL
AM cortisol (serum)

Track HPA axis response; one of the hormonal endpoints evaluated in the clinical study context

DHEA-S

Indirect marker of adrenal androgen output; 17-ketosteroid normalization was a study endpoint

Aldosterone (serum)

Aldosterone normalization was explicitly measured as an endpoint in the sole clinical study

Glandokort Before and After

Days 1-5

No significant changes expected. The peptide complex begins interacting with adrenal tissue.

Days 6-15

Some users report subtle improvements in energy levels, stress tolerance, and mood stability based on anecdotal reports.

Days 16-30

The clinical study observed improvements in performance, mood, and sleep quality by the end of a 30-day course. Hormonal markers showed normalization.

Weeks 5-12
post-course

Effects are proposed to persist after the course ends due to ongoing gene expression changes in adrenal tissue.

What to Expect

Days 1 to 5 (Initiation): Nothing happens that you'll notice. The A-17 peptide complex is proposed to begin binding adrenal cortex gene promoter regions during this window, but no clinical measurements exist for the first five days. Most users report zero effects in week one. Possible mild GI adjustment from the oral capsules is about it.

Days 6 to 15 (Early adaptation): Some users report subtle shifts in stress tolerance and mood stability around this point. The proposed mechanism involves early upregulation of steroidogenesis gene expression in CYP11B2 and DHEA pathways, though no clinical marker data exists for this specific interval. Distinguishing real effects from placebo here is genuinely difficult.

Days 16 to 30 (Peak course period): This is where the clinical study measured its endpoints. The 36 study participants showed improvements in physical and mental performance, mood, and sleep quality. Aldosterone and 17-ketosteroid levels normalized. Community reports align: better sleep, less burnout sensation, more stable stress response. No side effects were observed in the study; theoretical risks include mild GI discomfort and rare allergic reaction.

Weeks 5 to 12, post-course (Carry-over and washout): The Khavinson model proposes that epigenetic gene expression changes persist after you stop taking the capsules. Users anecdotally describe sustained effects for weeks to months. Isolating this from natural stress pattern changes or placebo is nearly impossible. Most people repeat their course at 3 to 6 month intervals based on when benefits seem to fade.

Detailed Timeline: Science vs Community

Days 1–5
Science

No observable changes; proposed initial binding of short-chain peptides to adrenal cortex gene promoter regions. No clinical measurements exist for this early window.

Community

Nothing noticeable. Most users report no effects in the first week.

Days 6–15
Science

Proposed early upregulation of steroidogenesis gene expression (CYP11B2, DHEA pathways). No clinical marker data exists for this interval specifically.

Community

Anecdotal reports of subtle improvements in stress tolerance and mood stability. Difficult to distinguish from placebo in this context.

Days 16–30
Science

Clinical study endpoint: improvements in physical and mental performance, mood, sleep quality; aldosterone and 17-ketosteroid normalization measured in study participants.

Community

Community anecdotes align: better sleep quality, reduced burnout sensation, improved energy levels. Stress response described as more stable.

Weeks 5–12 (post-course)
Science

Epigenetic gene expression changes proposed to persist beyond course completion. Hormonal normalization may continue without active dosing per the bioregulator model.

Community

Users anecdotally report sustained effects for weeks to months after the course ends. Hard to isolate from natural stress pattern changes or placebo. Most repeat at 3–6 months.

Pharmacokinetics

Half-Life
2h
Bioavailability
Oral: not formally characterized; assumed low for peptide complex
Tmax
Not established
Data Confidence
low

Source: Estimated from general short peptide pharmacokinetics; no Glandokort-specific PK studies published

Pharmacokinetics: Active Dose Over Time

t½ = ~1-4 hours (estimated, short peptide complex)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Glandokort

  • Individuals with chronic adrenal cortex insufficiency
  • People experiencing prolonged occupational or psycho-emotional stress
  • Adults with HPA axis dysfunction
  • Those seeking non-invasive adrenal support through oral peptide bioregulation

Related Peptides

What Changed for Glandokort

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Peptide Regulation of Gene Expression: A Systematic Review (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Short Peptides Regulate Gene Expression (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store in original packaging at room temperature, protected from moisture and direct light
After Reconstitution
N/A — oral capsule formulation
Temperature
15-25°C (59-77°F)

Frequently Asked Questions

Don't expect immediate effects. The single clinical study observed improvements in physical and mental performance, mood, and sleep by the end of a 30-day course. The mechanism is gradual epigenetic modulation of adrenal tissue gene expression. Not direct hormonal stimulation. Some users notice subtle shifts in stress tolerance around days 6-15.

The clinical study actually combined it with adaptogens without issues, and the Khavinson protocol routinely includes adaptogen therapy. But avoid combining with pharmaceutical corticosteroids (prednisone, hydrocortisone) without medical supervision; cumulative adrenal stimulation could disrupt HPA axis function.

Unknown. The clinical study only enrolled patients with diagnosed adrenal cortex insufficiency. Not "adrenal fatigue," which isn't a recognized medical diagnosis. No studies exist in people with normal adrenal function. Community anecdotes suggest benefit, but placebo effects in this context are significant.

Standard adrenal glandulars contain dried whole adrenal tissue; cortex and medulla. Glandokort uses purified short-chain peptides (<5,000 Da) extracted specifically from the adrenal cortex. The proposed mechanism is DNA interaction and gene expression modulation rather than direct hormone provision. The short peptide fragments should survive partial digestion better than whole protein extracts.

One unindexed clinical study from the developer's own institution (St. Petersburg Institute of Bioregulation) showed improvements in 36 patients. No independent replications, no placebo control, no blinding, and it wasn't published in a PubMed-indexed journal. The broader Khavinson bioregulator framework has some support, but Glandokort-specific evidence is thin.